APA (7th ed.) Citation

AY, A., SA, A., HO, A., Z, A., MA, Z., RA, M., . . . AM, H. (2026). HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials. Journal of the National Comprehensive Cancer Network : JNCCN, 24(3.5), . https://doi.org/10.6004/jnccn.2025.7459

Chicago Style (17th ed.) Citation

AY, Abuhelwa, Almansour SA, Al-Shamsi HO, Abuhelwa Z, Ziade MA, McKinnon RA, Sorich MJ, and Hopkins AM. "HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials." Journal of the National Comprehensive Cancer Network : JNCCN 24, no. 3.5 (2026). https://doi.org/10.6004/jnccn.2025.7459.

MLA (9th ed.) Citation

AY, Abuhelwa, et al. "HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 24, no. 3.5, 2026, https://doi.org/10.6004/jnccn.2025.7459.